دورية أكاديمية
Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis.
| العنوان: | Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis. |
|---|---|
| المؤلفون: | Cain AR; Allegheny Health Network, Pittsburgh, Pennsylvania, USA., Bremmer DN; Allegheny Health Network, Pittsburgh, Pennsylvania, USA., Carr DR; Allegheny Health Network, Pittsburgh, Pennsylvania, USA., Buchanan C; Allegheny Health Network, Pittsburgh, Pennsylvania, USA., Jacobs M; Allegheny Health Network, Pittsburgh, Pennsylvania, USA., Walsh TL; Allegheny Health Network, Pittsburgh, Pennsylvania, USA., Moffa MA; Allegheny Health Network, Pittsburgh, Pennsylvania, USA., Shively NR; Allegheny Health Network, Pittsburgh, Pennsylvania, USA., Trienski TL; Allegheny Health Network, Pittsburgh, Pennsylvania, USA. |
| المصدر: | Open forum infectious diseases [Open Forum Infect Dis] 2021 Dec 18; Vol. 9 (2), pp. ofab589. Date of Electronic Publication: 2021 Dec 18 (Print Publication: 2022). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Published by Oxford University Press on behalf of the Infectious Diseases Society of America Country of Publication: United States NLM ID: 101637045 Publication Model: eCollection Cited Medium: Print ISSN: 2328-8957 (Print) Linking ISSN: 23288957 NLM ISO Abbreviation: Open Forum Infect Dis Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Cary, NC : Published by Oxford University Press on behalf of the Infectious Diseases Society of America, [2014]- |
| مستخلص: | Background: Preliminary data suggest that the effectiveness of dalbavancin may be similar to current standard-of-care (SoC) treatment options for osteomyelitis with an advantageous dosing schedule. Methods: This was a retrospective, observational cohort study of adult patients diagnosed with osteomyelitis. Patients were matched 1:2 to dalbavancin (administered as 2 doses separated by 1 week) or SoC treatment for osteomyelitis according to the Charlson Comorbidity Index, site of infection, and causative pathogen. The primary objective was to determine the incidence of treatment failure after a 1-year follow-up period. Secondary objectives included hospital length of stay (LOS), infection-related 1-year readmission rates, and treatment-related adverse events. Results: A total of 132 patients received dalbavancin (n = 42) or SoC (n = 90). Baseline characteristics, including rates of surgical intervention, were similar between the 2 treatment groups. Treatment failure was similar between those who received dalbavancin and SoC (21.4% vs 23.3%; P = .81). Patients who received dalbavancin had a shorter hospital LOS (5.2 days vs 7.2 days; P = .01). There was no difference in the rates of infection-related readmission between the dalbavancin and the SoC group (31% vs 31.1%; P = .99). There were numerically fewer adverse events in the dalbavancin group compared with the SoC group (21.4% vs 36.7%; P = .08). Peripherally inserted central catheter line-related complications were reported in 17.8% of patients in the SoC group. Conclusions: Dalbavancin administered as a 2-dose regimen is a safe and effective option for the treatment of osteomyelitis. (© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.) |
| References: | Am J Kidney Dis. 2012 Oct;60(4):510-3. (PMID: 22985979) Clin Infect Dis. 2012 Jun;54(12):e132-73. (PMID: 22619242) Int J Antimicrob Agents. 2018 Apr;51(4):608-611. (PMID: 29277526) Lancet. 2004 Jul 24-30;364(9431):369-79. (PMID: 15276398) BMJ Qual Saf. 2019 Jul;28(7):574-581. (PMID: 30683751) Clin Infect Dis. 2015 Sep 15;61(6):e26-46. (PMID: 26229122) Clin Infect Dis. 2012 Feb 1;54(3):393-407. (PMID: 22157324) J Antimicrob Chemother. 2020 Oct 1;75(10):2717-2722. (PMID: 32457989) Open Forum Infect Dis. 2018 Dec 10;6(1):ofy331. (PMID: 30648126) N Engl J Med. 2019 Jan 31;380(5):425-436. (PMID: 30699315) Antimicrob Resist Infect Control. 2017 Jan 28;6:18. (PMID: 28149507) Antimicrob Agents Chemother. 2015 Apr;59(4):1849-55. (PMID: 25561338) J Infect. 2010 May;60(5):338-43. (PMID: 20230854) Clin Infect Dis. 2011 Feb 1;52(3):e18-55. (PMID: 21208910) |
| فهرسة مساهمة: | Keywords: dalbavancin; osteomyelitis |
| تواريخ الأحداث: | Date Created: 20220124 Latest Revision: 20220430 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8773963 |
| DOI: | 10.1093/ofid/ofab589 |
| PMID: | 35071682 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!